Sofinnova Crossover I SLP 13D and 13G filings for Abivax S.A.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-11 12:50 pm Sale | 2026-05-07 | 13D | ABIVAX SA SPONSORED ADS ABVX | Sofinnova Crossover I SLP | 5,499,478 6.700% | -900,000 (-14.06%) | Filing |
| 2026-01-14 4:13 pm Sale | 2026-01-12 | 13D | ABIVAX SA SPONSORED ADS ABVX | Sofinnova Crossover I SLP | 6,399,478 7.700% | -2,000,000 (-23.81%) | Filing |
| 2025-10-30 4:08 pm Sale | 2025-10-28 | 13D | ABIVAX SA SPONSORED ADS ABVX | Sofinnova Crossover I SLP | 8,399,478 9.400% | -1,200,000 (-12.50%) | Filing |
| 2025-07-31 4:04 pm Purchase | 2025-07-23 | 13D | ABIVAX SA SPONSORED ADS ABVX | Sofinnova Crossover I SLP | 9,599,478 11.400% | 1,805,000 (+23.16%) | Filing |
| 2025-02-14 4:19 pm Purchase | 2025-02-14 | 13D | ABIVAX SA SPONSORED ADS ABVX | Sofinnova Crossover I SLP | 7,794,478 11.000% | 845,865 (+12.17%) | Filing |
| 2023-10-30 1:42 pm Purchase | 2023-10-20 | 13D | ABIVAX SA SPONSORED ADS ABVX | Sofinnova Crossover I SLP | 6,948,613 8.000% | 6,948,613 (New Position) | Filing |